Check for updates

Leptin/adiponectin ratio as a prognostic factor for increased weight gain in girls with central precocious puberty

Jessie Nallely Zurita-Cruz[1], Miguel Angel Villasís-Keever[2]*,
Leticia Manuel-Apolinar[3], Leticia Damasio-Santana[3],
Eulalia Garrido-Magaña[4] and Aleida de Jesús Rivera-Hernández[4]

[1]Medicine Faculty of Autonomous National University, Clinical Research Department, Hospital Infantil de México Federico Gómez, Ciudad de Mexico, Mexico, [2]Unit of Analysis and Synthesis of the Evidence, National Medical Center XXI Century, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico, [3]Department of Endocrinology Research, Hospital of Medical Specialties, National Medical Center XXI Century, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico, [4]Department of Pediatric Endocrinology, Children's Hospital, National Medical Center XXI Century, Instituto Mexicano del Seguro Social, Ciudad de Mexico, Mexico

Objective: To determine if the leptin, adiponectin, and leptin/adiponectin ratio (LAR) can predict weight gain at the end of GnRH analogs (GnRHa) treatment in girls with central precocious puberty (CPP).

Material and methods: Study design: prospective cohort. Serum levels of leptin and adiponectin were determined at diagnosis of CPP. Anthropometry was performed at diagnosis of CPP and every six-months, until treatment with GnRHa was discontinued and they presented menarche. Patients were divided according to BMI<94 and BMI>95 percentile at diagnosis of CPP. The outcome was the increased in weight gain (e.g., from normal weight to overweight) at the end of follow-up. Statistical analysis: repeated measures ANOVA test and Student's t-test were used to compare groups. Logistic regression analysis was used to evaluate the association of leptin and adiponectin levels, as well as LAR values with increased weight gain.

Results: Fifty-six CPP patients were studied, 18 had BMI >95 percentile and 38 BMI <94 percentile. Of the 18 patients who initially had BMI >95th, two patients went from obesity to overweight, while among the 38 patients who started with BMI <94th, 21 (55.2%) increased their weight gain at the end of follow-up. This last group had higher leptin levels (8.99 $\pm$ 0.6 *vs* 6.14 $\pm$ 0.8, p=0.005) and higher LAR values compared to those who remained in the same weight (1.3 $\pm$ 0.5 *vs* 0.96 $\pm$ 0.56, p=0.01). In the logistic regression analysis, it was found that higher leptin levels and higher LAR values were associated with increased weight gain (RR 1.31, 95%CI 1.03-1.66, RR 4.86, 95%CI 1.10-21.51, respectively), regardless of birth weight, pubertal stage, age, and bone/chronological age ratio.

Conclusions: In patients with CPP, leptin levels and higher LAR values appear to be associated with significantly greater weight gain during GhRHa treatment, particularly in girls starting with BMI < 94 percentile.

Introduction

Central precocious puberty (CPP) is defined as the development of sexual characteristics before 9 years of age in boys and 8 years of age in girls due to activation of the hypothalamic-pituitary-gonadal axis (1, 2). CPP is a rare disease, with an estimated incidence of 1:10,000, but predominantly occurs in girls in more than 95% of cases (3, 4). There are many theories regarding the etiology of idiopathic CPP. One of which points out that these girls have a higher percentage of body fat for their chronological age, where leptin has a main role (5). Leptin acts through its receptor to stimulate the secretion of kisspeptin, a hypothalamic hormone, which in turn promotes the secretion of GnRH in the arcuate nucleus (6, 7).

It is common for girls with CPP to be overweight or obese at the time of diagnosis, but there are conflicting results as to whether weight is increased during or after receiving treatment with GnRH analogs (GnRHa), because there are studies indicating that the BMI increases and in others that it decreases (8–13). However, CPP is considered to be a risk factor for the development of cardiometabolic disorders in adult life, regardless of the presence of obesity (14, 15).

Adipose tissue is considered an endocrine organ that produces a wide variety of biologically active adipokines, such as leptin, adiponectin, tumor necrosis factor-α and interleukin-6 (16).

These adipokines plays a pathophysiological link between dysfunctional adipose tissue and cardiometabolic factors (17). Leptin is produced proportionally to the amount of body fat, and in patients with obesity there is an association of high leptin levels with cardiometabolic factors and metabolic syndrome (18, 19), while high levels of adiponectin are associated with a better metabolic profile in these patients (20). However, it has been observed that the leptin/adiponectin ratio (LAR) identify dysfunctional adipose tissue more accurately (21, 22). Thus, higher LAR values have been considered a better marker of insulin resistance and metabolic syndrome than serum leptin or adiponectin levels (23). Although the possible role of LAR in girls with CPP has not been studied, it is hypothesized that higher LAR values are a better predictor of weight gain than high leptin levels or low adiponectin levels.

The aim of this study was to determine if the leptin, adiponectin levels, and LAR can predict weight gain at the end of GnRha treatment in girls with CPP.

Material and methods

Subjects

A prospective cohort study was performed from January 2012 to May 2019 at a tertiary care pediatric center in Mexico City. For 36 months, we followed a cohort of Mexican girls <8 years of age with CPP. All included patients were selected using a consecutive sampling technique. At the time of diagnosis, subjects were classified as Tanner stages II and III. Follow-up started at the time of CPP diagnosis and initiation of leuprolide treatment. We excluded patients with any other disease or therapy associated with weight gain or increased appetite, such as intracranial tumors, Cushing disease, genetic syndromes (e.g., Prader-Willi, Bardet-Biedl, or Alstrom), use of steroids, fluoxetine, insulin sensitizers, hyporexigens, growth hormone, intestinal fat absorption inhibitors, or low birthweight (24).

We found 72 patients who fulfilled the inclusion criteria; but nine patients were excluded: three due to congenital adrenal hyperplasia, four due to low birthweight, and two because the parents did not agree to their daughter participating in the study. Finally, seven patients were eliminated because they were lost to follow-up. Thus, 56 patients were analyzed.

Leuprolide (GnRha) treatment consisted of monthly intramuscular application from diagnosis, discontinuing when patients reached a chronological age of 11 to 12 years, bone age 13 years or older, and growth velocity slowed to <4 cm/year (25–27). Subsequently, the patients continued to be monitored, until they presented menarche, which was the final moment of follow-up.

The research protocol was approved by the hospital ethics and research committee. Parents signed the informed consent and child assent according to the recommendations of the Declaration of Helsinki.

Definitions

Diagnosis of CPP was made according to the following clinical criteria: Tanner breast stage II or higher, height acceleration, advancement of bone age (28) and confirmed by GnRHa stimulation test. This test is carried out with the application of 3.75 of GnRHa (leuprolide) and, after two hours, luteinizing hormone (LH) levels are measured (29). CPP is diagnosed with

LH levels >7 mU/ml (29, 30). Adequate suppression of pituitary −gonadal function was defined as a stimulated plasma LH level after GnRH stimulation <6.5 mU/ml at 3, 12, 24 and 36 months, after treatment initiation with GnRHa (29).

Increase in weight gain and in BMIz, until the last evaluation were the primary outcomes measures. A BMI <84 percentile was considered normal weight, while a BMI between 84 and 95 percentile was considered overweight, and obesity when BMI was >95 percentile (31).

Serum leptin and adiponectin measurements

Twelve-hour fasting serum leptin levels were measured between 7:00 and 8:00 a.m. using venipuncture samples at study onset and at a 12-month follow-up. Plasma samples were frozen at -20°C and analyzed. Leptin and adiponectin levels were measured using an enzyme-linked immunosorbent assay (ELISA) (Human Leptin DuoSet DY 398, R&D Systems, Minneapolis, MN, USA) (Human Adiponectin DuoSet DY 1065, R&D Systems, Minneapolis, MN, USA). All ELISA experiments were determined using Finstruments Multiskan EX (MTX Lab Systems Inc., Vienna, VA, USA) in duplicate per the manufacturer's recommendations. The intra- and inter-assay coefficients of variation for all measurements were <7%. A standard curve was also included within each assay. The LAR was obtained by dividing the serum concentrations of leptin by those of adiponectin.

Anthropometry

The patients' anthropometric measurements were noted by a certified nutritionist and included height, weight, and body fat percentage by bioimpedance (Tanita BC-568 segmental analyzer, Tokyo, Japan). These anthropometric data were assessed every six months until the end of the follow-up.

Statistics analyses

The Shapiro-Wilk test was applied to the quantitative variables, and a nonparametric distribution was observed. The quantitative variables were normalized by taking the logarithmic, except LAR distribution was normalized by taking the square root. We calculated the mean and standard error (SE) of quantitative variables.

Since patients with normal weight and overweight had increased weight gain compared to those with obesity, at the end of follow-up, two groups were formed according to the baseline BMI percentile (<94 and >95), to carry out all the analyses.

To determine differences in BMIz at study onset and after 12, 24 months, end of treatment and menarche, statistical analysis was performed using repeated measures ANOVA test and Student's t-test to compare groups.

A logistic regression analysis was used to determine the association of LAR with increased weight gain, adjusted by birthweight, pubertal stage, age, and bone/chronological age ratio.

A p value <0.05 was considered statistically significant. STATA v.14.0 was used for all statistical analyses.

Results

Baseline

At diagnosis, the mean age of the 56 patients was 7.0 ± 0.18 years, mean bone age was 10.0 ± 0.26 years, and all patients had a bone/chronological age ratio >1. Of the total, 33 patients (58.9%) had puberty onset in Tanner breast stage II, and 23 patients (41.1%) were in breast stage III (see Table 1). The BMIz mean was 1.22 ± 0.12; 25 patients (44.6%) had normal BMIz, 13 patients (23.2%) had overweight, and 18 patients (32.1%) had obesity (Table 1 and Figure 1).

Follow-up

During the follow-up, 22 patients (40%) discontinued leuprolide at 24 months of treatment, and 34 patients at 36 months. In all patients, mean BMIz increased throughout follow-up (Figure 1A); at the beginning it was 1.22 ± 0.12, at 12 months was 1.35 ± 0.11 (p=0.053), at 24 months 1.39 ± 0.11 (p=0.069), while at the end of leuprolide was 1.46 ± 0.12 (p=0.006), finally, when menarche occurred, between 12 and 18 months after stopping leuprolide, the BMIz was 1.58 ± 0.17 (p=0.157). However, when comparing those with BMI <94 and >95 percentile at diagnosis, it was observed that the first group had an increase in BMIz (mean 0.73 vs. 1.27, p=0.01) (Figure 1B), contrary to a decrease in the second group (mean 2.26 vs. 2.10; p=0.15) (Figure 1C).

Likewise, of the 18 patients who initially had BMI >95th only two patients went from obesity to overweight (Figure 2B). While among the 38 patients who started with BMI <94th, 21 (55.2%) increase in weight gain; as shown in Figure 2A, in the last assessment 15 were classified as obese, 10 as overweight, and 13 as normal weight.

Adipocytokines

At study onset, the mean leptin value was 8.3± 0.47 ng/ml, and levels were similar according to pubertal developmental stage (Tanner stage II, 8.04 ± 0.60 ng/ml vs Tanner stage III, p=0.220), but as shown in Table 1, in the BMI <94 group the mean was lower than in the BMI >95 group (p=0.020). And as for adiponectin, the BMI >95 group had lower values than the BMI <94 group, (p=0.020). When analyzing the patients with BMI <94th at baseline, among the 21 patients who had a increase in weight gain, leptin levels were higher than the group of 17 patients who

TABLE 1 Baseline characteristics of 56 girls with central precocious puberty, according to the BMI at the beginning of follow-up.

		All patients	BMI <94 percentile	BMI >95 percentile
		n=56	n=38	n=18
		Mean ± SE		
Chronological age, years		7.0 ± 0.18	6.8 ± 0.24	7.4 ± 0.18
Bone age, years		10.0 ± 0.26	9.6± 0.35	10.9 ± 0.26
Birth weight, kg		2.9 ± 0.56	2.8 ± 0.73	3.0 ± 0.79
BMI z-score		1.22 ± 0.12	0.73 ± 0.11	2.26 ± 0.08
Stratification according to BMI percentiles	Normal	25 (44.6)	25 (65.8)	0 (0)
	Overweight	13 (23.2)	13 (34.2)	0 (0)
	Obesity	18 (32.2)	0 (0)	18 (100)
Puberal stage, Tanner*	2	33 (58.9)	23 (60)	10 (55.5)
	3	23 (41.1)	15 (39)	8 (44.4)
Leuprolide dose, mg/month*	3.75	48 (85.7)	33 (86.8)	15 (83.3)
	7.5	8 (14.2)	6 (13.2)	3 (16.7)
Leptin, ng/ml		8.30 ± 0.47	7.72± 0.35	9.68 ± 0.77
Adiponectin, mg/dl		6.73 ± 0.23	7.07 ± 0.26	6.01 ± 0.45
Leptin/adiponectin ratio		1.37 ± 0.11	1.15 ± 0.09	1.84 ± 0.26

SE, estándar error; * Frecuency (%).

remained unchanged (8.99 ± 0.6 vs 6.14 ± 0.8, p=0.005), but the levels of adiponectin were similar between both groups (7.00 ± 0.4 vs 7.16 ± 0.3, p=0.61).

Regarding LAR at diagnosis, in the 56 patients the mean value was 1.37± 0.11; but in the BMI <94th girls was lower (mean 1.15 ± 0.09), compared to the BMI >95th group (mean 1.84 ± 0.26), p=0.012. As shown in Figure 3A, in the 21 patients with increased in weight gain, the values were statistically significantly higher, compared to those of the 17 patients who remained unchanged, 1.30 ± 0.5 vs 0.96 ± 0.5, p=0.01. The data were similar when comparing the values in those who started with normal weight (Figure 3B) or with overweight (Figure 3C), but the LAR mean value was higher in this last group (1.48 ± 0.16).

Finally, multivariate analyses are presented in Tables 2, 3 performed on the 38 patients with BMI<94th; as shown, both leptin levels and LAR were significantly associated with increased in weight gain, regardless of birthweight, pubertal stage, age, and bone/chronological age ratio; but the strength of association of LAR was greater than leptin levels, RR 1.31, 95%CI 1.03-1.66 vs RR 4.86, 95%CI 1.10-21.51, respectively.

Discussion

Different studies have shown that girls with CPP have a higher risk of weight gain during treatment with GnRHa, as well as having

FIGURE 1
(A) Modification of BMI Z-score in all girls with CCP. (B) Modification of BMI Z-score in girls with BMI<94 percentile at diagnosis. (C) Modification of BMI Z-score in girls with BMI>95 percentile at diagnosis.

FIGURE 2
(A) Modification of nutrition status in girls with BMI<94 percentile at diagnosis **(B)** Modification of nutrition status in girls with BMI>95 percentile at diagnosis.


FIGURE 3
(A) Leptin/adiponectin ratio (LAR) values in CCP girls with BMI <94 percentile and who had an increased weight gain **(B)** LAR values in CPP girls with BMI <84 percentile and who had increased in weight gain **(C)** LAR values in CPP girls with BMI >85 and <94 percentile and who had an increased in weight gain.

a more adverse cardiometabolic profile, but information on possible associated factors is lacking. To our knowledge, this is the first study to identify LAR as a prognostic marker associated with increased in weight gain in patients with CPP.

Our findings may be relevant, since there is controversy about whether the greater adiposity that CPP patients have at diagnosis may be the main factor related to in the increased cardiovascular risk. In general, these patients tend to increase zBMI, but when analyzed according to their baseline nutritional status, it has been found that CPP girls with normal weight at diagnosis, their zBMI increases more than when they are classified as overweight/obese (8, 9). Park J et al. included 59 patients, of whom 35.6% were overweight or obese; during follow-up until final height was reached, no change in zBMI was observed, but in patients who started overweight/obese, there was a decrease in zBMI (p<0.05) (13). Similarly, in this study, the increase in zBMI was statistically significant in the 38 patients with BMI < 94th (Figure 1B), and almost all of those with BMI >95th remained in the same zBMI.

Adipose tissue is metabolically active and secretes adipokines, such as leptin and adiponectin; the former causes vascular inflammation and insulin resistance, while the latter inhibits adherence molecules and increases the production of anti-inflammatory cytokines, such as IL-10 (32–34). In addition, leptin has been shown to be useful prognostic factor in weight gain and in the development of type 2 diabetes mellitus (35, 36). LAR represents a marker of the pathophysiological function of both adipokines and may indicate an imbalance in proinflammatory and anti-inflammatory conditions, as well as adipose tissue dysfunction (37). Under normal conditions, the ratio of leptin and adiponectin is 1:2, which means LAR values of 0.5; thus, higher values have been associated with an increase in cardiovascular risk (21).

To verify the relationship between leptin and adiponectin, studies have been carried out in human white preadipocytes. Singh et al. reported that leptin may regulate adiponectin mRNA *via* extracellular signal-regulated kinase (ERK)-dependent activation of signal transducer and activator of transcription 3 (STAT3), but in obese people these pathways are altered (38).

Adipose tissue dysfunction has been regarded as a form of oxidative stress, in which thiobarbituric acid reactive sub-stances (TBARS) are increased, as well as C-reactive protein (CRP), serum amyloid A (SAA) and osteopontin (OPN) levels (39–42). In adult patients with metabolic syndrome, a positive correlation of LAR levels with CRP has been described, suggesting that adipose tissue dysfunction is related to elevated LAR values (23). This information

TABLE 2 Logistic regression model to determine the association of factors related to the increased weight gain, with leptin and adiponectin levels (n=38).

	RR	CI 95%	P
Leptin, ng/ml	1.31	1.03-1.66	0.026
Adiponectin, mg/dl	0.91	0.57-1.44	0.703
Birth weight, kg	0.99	0.99-1.001	0.908
Puberal stage, Tanner	1.09	0.20-5.85	0.919
Chronological age	0.61	0.32-1.15	0.128
Normal weight and overweight at diagnosis	1.86	0.34-10.09	0.471

RR, Relative Risk; CI, Confidence Interval.

TABLE 3 Logistic regression model to determine the association of factors related to the increased weight gain, with leptin/adiponectin ratio (n=38).

	RR	CI 95%	P
Leptin/adiponectin ratio (LAR)	4.86	1.10-21.51	0.037
Birth weight, kg	0.99	0.99-1.001	0.949
Puberal stage, Tanner	0.74	0.15-3.16	0.327
Chronological age	0.64	0.05-10.58	0.717
Normal weight and overweight at diagnosis	0.77	0.21-2.7	0.690

RR, Relative Risk; CI, Confidence Interval.

is consistent with findings from more recent studies in which LAR values could be a more efficient predictor of obesity-related complications compared to leptin or adiponectin levels (41, 43, 44).

LAR values have also been evaluated in children. Some studies in patients without comorbidities with 6-years of follow-up have reported that high leptin levels and LAR are predictors in nonobese subjects. However, it is controversial which of the two is a better predictor; Zhang et al, identified leptin as being better than LAR in change of zBMI (leptin β=0.209 and LAR β=0.146), while Li et al, observed that LAR was better than leptin in change of body fat percentage (leptin β=0.310 and LAR β=0.420) (45, 46). Among girls with CCP we also found that leptin levels and LAR are associated with increased in weight gain, but LAR seems a better marker (Tables 2, 3). In contrast, Yoo JM et al. reported that neither leptin, adiponectin, nor LAR were predictors of weight gain girls with CPP (47); this difference could be due to a shorter follow-up time, or because the analysis was not limited to patients with greater weight gain, as in the present study.

Therefore, we consider that, at the diagnosis of CPP, leptin levels and LAR can be used as a prognostic marker to identify those girls who are at greater risk of significantly increasing their weight during treatment with GnRHa. This would help to offer early interventions to reduce the probability of developing comorbidities related to obesity in adulthood, such as metabolic syndrome, polycystic ovarian syndrome, and type 2 diabetes (48, 49).

As for the limitations of the study, we should mention that the sample size was small, so it seems necessary to carry out more studies to verify our findings. Likewise, in other studies, an attempt should be made to establish the LAR cut-off point that identifies patients with a higher risk of increasing their zBMI.

Conclusions

In patients with CPP, higher leptin levels and LAR values appear to be associated with significantly greater weight gain during GhRHa treatment, particularly in girls starting with BMI < 94 percentile.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the research protocol by the Hospital de Pediatria National Medical Center XXI Century, Instituto Mexicano del Seguro Social ethics and research committee. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

Author contributions

Conceptualization, methodology & formal analysis: MV-K & JZ-C. Investigation: JZ-C, LM-A, LD-S, EG-M, AR-H. Writing, review & editing: MV-K & JZ-C. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Shankar R PO. Precocious puberty. *Adv Endocrinol Metab* (1995) 6:55–89.

2. Kaplowitz P, Oberfield S. Reexamination of the age limit for defining when puberty is precocious in girls in the united states: Implications for evaluation and treatment. *Pediatrics* (1999) 104:936–41. doi: 10.1542/peds.104.4.936

3. Bridges NA, Christopher JA, Hindmarsh PC, Brook CGE. Sexual precocity: Sex incidence and aetiology. *Arch Dis Child* (1994) 70(2):116–8. doi: 10.1136/adc.70.2.116

4. Partsch CJ, Heger S, Sippell WGE. Management and outcome of central precocious puberty. *Clin Endocrinol* (2002) 56(2):129–48. doi: 10.1046/j.0300-0664.2001.01490.x

5. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. *Nature* (1998) 395(6704):763–70. doi: 10.1038/27376

6. Wakabayashi Y, Nakada T, Murata K, Ohkura S, Mogi K, Navarro VM, et al. Neurokinin b and dynorphin a in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile gonadotropin-releasing hormone secretion in the goat. *J Neurosci* (2010) 30(8):3124–32. doi: 10.1523/JNEUROSCI.5848-09.2010

7. Donato JJr, Cravo RM, Frazão R, Gautron L, Scott MM, Lachey J, et al. Leptin's effect on puberty in mice is relayed by the ventral premammillary nucleus and does not require signaling in Kiss1 neurons. *J Clin Invest* (2011) 121(1):355–68. doi: 10.1172/JCI45106

8. Kim HR, Nam H-K, Rhie Y-J, Lee K-H. Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty. *Ann Pediatr Endocrinol Metab* (2017) 22(4):259–65. doi: 10.6065/apem.2017.22.4.259

9. Yang WJ, Ko KH, Lee KH, Hwang IT, Oh YJ. The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty. *Ann Pediatr Endocrinol Metab* (2017) 22(1):49. doi: 10.6065/apem.2017.22.1.49

10. Yoon JW, Park HA, Lee J, Kim JH. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty. *Korean J Pediatr* (2017) 60(12):395–402. doi: 10.3345/kjp.2017.60.12.395

11. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. *Eur J Endocrinol* (2004) 150(4):533–7. doi: 10.1530/eje.0.1500533

12. Sinthuprasith P, Dejkhamron P, Wejaphikul K, Unachak KE. Near final adult height, and body mass index in overweight/obese and normal-weight children with idiopathic central precocious puberty and treated with gonadotropin-releasing hormone analogs. *J Pediatr Endocrinol Metab* (2019) 32(12):1369–75. doi: 10.1515/jpem-2019-0136

13. Park J, Hwang TH, Kim YD, Han HS. Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level. *Ann Pediatr Endocrinol Metab* (2018) 23(1):14–20. doi: 10.6065/apem.2018.23.1.14

14. Lee HS, Yoon JS, Roh JK, Hwang JS. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty. *Endocrine* (2016) 54(2):497–503. doi: 10.1007/s12020-016-1023-5

15. Colmenares A, Gunczler P, Lanes R. Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment. *Int J Pediatr Endocrinol* (2014) 2014(1):5. doi: 10.1186/1687-9856-2014-5

16. Crewe C, An YA, Scherer PEE. The ominous triad of adipose tissue dysfunction: Inflammation, fibrosis and impaired angiogenesis. *J Clin Invest* (2017) 127:74–82. doi: 10.1172/JCI88883

17. Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán VE. Adipokine dysregulation and adipose tissue inflammation in human obesity. *Eur J Clin Invest* (2018) 48:e12997. doi: 10.1111/eci.12997

18. Rodríguez A, Ezquerro S, Méndez-Giménez L, Becerril S, Frühbeck G. Revisiting the adipocyte: A model for integration of cytokine signaling in the regulation of energy metabolism. *Am J Physiol Endocrinol Metab* (2015) 309:E691–714. doi: 10.1152/ajpendo.00297.2015

19. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. *Metabolism* (2015) 64:131–45. doi: 10.1016/j.metabol.2014.10.016

20. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. *Cell Metab* (2016) 23:770–84. doi: 10.1016/j.cmet.2016.04.011

21. Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. relation with obesity-associated cardiometabolic risk. *Adipocyte* (2018) 7:57–62. doi: 10.1080/21623945.2017.1402151

22. Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. *J Obes* (2013) 2013:409679. doi: 10.1155/2013/409679

23. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. *Sci Rep* (2017) 7:6619. doi: 10.1038/s41598-017-06997-0

24. Miras M, Ochetti M, Martín S, Silvano L, Sobrero G, Castro L, et al. Serum levels of adiponectin and leptin in children born small for gestational age: Relation to insulin sensitivity parameters. *J Pediatr Endocrinol Metab* (2010) 23(5):463–71. doi: 10.1515/jpem.2010.077

25. Heger S, Partsch CJ, Peter M, Blum WF, Kiess W, Sippell WG. Serum leptin levels in patients with progressive central precocious puberty. *Pediatr Res* (1999) 46(1):71–5. doi: 10.1203/00006450-199907000-00012

26. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: Impact on adult height, body mass index, bone mineral content, and reproductive function. *J Clin Endocrinol Metab* (2008) 93(1):190–5. doi: 10.1210/jc.2007-1216

27. Wolters B, Lass N, Reinehr T. Treatment with gonadotropin-releasing hormone analogues: Different impact on body weight in normal-weight and overweight children. *Horm Res Paediatr* (2012) 78(5–6):304–11. doi: 10.1159/000346145

28. Tanner JM. Issues and advances in adolescent growth and development. *J Adolesc Heal Care* (1987) 8:470–8. doi: 10.1016/0197-0070(87)90048-9

29. Brito VN, Latronico AC, Arnhold IJP, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. *J Clin Endocrinol Metab* (2004) 89(9):4338–42. doi: 10.1210/jc.2003-031537

30. Carel J-C, Eugster EA, Rogol A, Ghizzoni L, Palmert MR. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics* (2009) 123(4):e752–62. doi: 10.1542/peds.2008-1783

31. Centers for Disease Control and Prevention. *CDC Growth charts* (2017). Available at: https://www.cdc.gov/nchs/data/series/sr_11/sr11_246.pdf.

32. Ouchi N WK. Adiponectin as an anti-inflammatory factor. *Clin Chim Acta* (2007) 380(1–2):24–30. doi: 10.1016/j.cca.2007.01.026

33. Candido GZ, Silva ILZ, Martins LT, Koczicki L, Kubo KS, Frigeri HR. Specific obesity-related adipokines. *Immunochem Immunopathol* (2015) 01(2):108. doi: 10.4172/2469-9756.1000108

34. Savoye M, Dziura J, Castle J, DiPietro L, Tamborlane WV, Caprio SE. Importance of plasma leptin in predicting future weight gain in obese children: A two-and-a-half-year longitudinal study. *Int J Obes Relat Metab Disord* (2002) 26(7):942–6. doi: 10.1038/sj.ijo.0802018

35. Chessler SD, Fujimoto WY, Shofer JB, Byoko EJ, Weigle DSE. Increased plasma leptin levels are associated with fat accumulation in Japanese-americans. *Diabetes* (1998) 47:239–243. doi: 10.2337/diab.47.2.239

36. Weber DR, Leonard MB, Shults J, Zemel BS. A comparison of fat and lean body mass index to BMI for the identification of metabolic syndrome in children and adolescents. *J Clin Endocrinol Metab* (2014) 99(9):3208–16. doi: 10.1210/jc.2014-1684

37. Singh P, Sharma P, Sahakyan KR, Davison DE, Sert-Kuniyoshi FH, Romero-Corral A, et al. Differential effects of leptin on adiponectin expression with weight gain versus obesity. *Int J Obes* (2016) 40(2):266–74. doi: 10.1038/ijo.2015.181

38. Gómez-Ambrosi J, Salvador J, Rotellar F, Silva C, Catalán V, Rodríguez A, et al. Increased serum amyloid a concentrations in morbid obesity decrease after gastric bypass. *Obes Surg* (2006) 16(3):262–9. doi: 10.1381/096089206776116525

39. Gómez-Ambrosi J, Catalán V, Ramírez B, Rodríguez A, Colina I, Silva C, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. *J Clin Endocrinol Met* (2007) 92(9):3719–27. doi: 10.1210/jc.2007-0349

40. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. *Nutrients* (2019) 11(2):454. doi: 10.3390/nu11020454

41. Gómez-Ambrosi J, Azcona C, Patiño-García A, Frühbeck G. Serum amyloid a concentration is increased in obese children and adolescents. *J Pediatr* (2008) 153:71–5. doi: 10.1016/j.jpeds.2008.01.006

42. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin: Adiponectin ratio with measures of insulin resistance in non-diabetic individuals. *Diabetologia* (2009) 52(11):2345–9. doi: 10.1007/s00125-009-1508-3

43. Thorand B, Zierer A, Baumert J, Meisinger C, Herder C, Koenig WE. Associations between leptin and the leptin/adiponectin ratio and incident type 2 diabetes in middle-aged men and women: Results from the MONICA/KORA augsburg study 1984–2002. *Diabetes Med* (2010) 27(9):1004–11. doi: 10.1111/j.1464-5491.2010.03043.x

44. Zhang M, Cheng H, Zhao X, Hou D, Yan Y, Cianflone K, et al. Leptin and leptin-to-Adiponectin ratio predict adiposity gain in nonobese children over a six-year period. *Child Obes* (2017) 13(3):213–21. doi: 10.1089/chi.2016.0273

45. Li S, Liu R, Arguelles L, Wang G, Zhang J, Shen X. Adiposity trajectory and its associations with plasma adipokine levels in children and adolescents-a prospective cohort study. *Obes (Silver Spring)* (2016) 24(2):408–16. doi: 10.1002/oby.21378

46. Yoo JW, Song CW, Lim HH. Leptin and adiponectin levels in girls with central precocious puberty before and during GnRH agonist treatment. *Ann Pediatr Endocrinol Metab* (2016) 21(4):199. doi: 10.6065/apem.2016.21.4.199

47. Ladeiras-Lopes R, Sampaio F, Bettencourt N, Fontes-Carvalho R, Ferreira N, Leite-Moreira A, et al. The ratio between visceral and subcutaneous abdominal fat assessed by computed tomography is an independent predictor of mortality and cardiac events. *Rev Esp Cardiol (Engl Ed)* (2017) 70(5):331–7. doi: 10.1016/j.recesp.2016.09.006

48. Chandrasekhar T, Suchitra MM, Pallavi M, Srinivasa Rao PVLN, Sachan A. Risk factors for cardiovascular disease in obese children. *Indian Pediatr* (2017) 54(9):752–5. doi: 10.1007/s13312-017-1169-0

49. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev* (2017) 18(7):715–23. doi: 10.1111/obr.12551